Literature DB >> 31325317

Neutrophil activation in septic acute kidney injury: A post hoc analysis of the FINNAKI study.

Sanna Törnblom1, Sara Nisula1, Suvi T Vaara1, Meri Poukkanen2, Sture Andersson3, Ville Pettilä1, Eero Pesonen4.   

Abstract

BACKGROUND: Inflammation, reflected by high plasma interleukin-6 concentration, is associated with acute kidney injury (AKI) in septic patients. Neutrophil activation has pathophysiological significance in experimental septic AKI. We hypothesized that neutrophil activation is associated with AKI in critically ill sepsis patients.
METHODS: We measured plasma (n = 182) and urine (n = 118) activin A (a rapidly released cytosolic neutrophil protein), interleukin-8 (a chemotactic factor for neutrophils), myeloperoxidase (a neutrophil biomarker released in tissues), and interleukin-6 on intensive care unit admission (plasma and urine) and 24 hours later (plasma) in sepsis patients manifesting their first organ dysfunction between 24 hours preceding admission and the second calendar day in intensive care unit. AKI was defined by the Kidney Disease: Improving Global Outcomes criteria.
RESULTS: Plasma admission interleukin-8 (240 [60-971] vs 50 [19-164] pg/mL, P < .001) and activin A (845 [554-1895] vs 469 [285-862] pg/mL, P < .001) were but myeloperoxidase (169 [111-300] vs 144 [88-215] ng/mL, P = .059) was not higher among patients with AKI compared with those without. Urine admission interleukin-8 (50.4 [19.8-145.3] vs 9.5 [2.7-28.7] ng/mL, P < .001) and myeloperoxidase (7.7 [1.5-12.6] vs 1.9 [0.4-6.9] ng/mL, P < .001) were but activin A (9.7 [1.4-42.6] vs 4.0 [0.0-33.0] ng/mL, P = .064) was not higher in AKI than non-AKI patients. Urine myeloperoxidase correlated with urine interleukin-8 (R = .627, P < .001) but not with plasma myeloperoxidase (R = .131, P = .158).
CONCLUSION: Interleukin-8 in plasma and urine was associated with septic AKI. Elevated plasma activin A indicates intravascular neutrophil activation in septic AKI. Concomitant plasma and urine myeloperoxidase measurements suggest neutrophil accumulation into injured kidneys.
© 2019 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  activin A; acute kidney injury; critical illness; intensive care; interleukin-6; interleukin-8; myeloperoxidase; sepsis

Year:  2019        PMID: 31325317     DOI: 10.1111/aas.13451

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  6 in total

Review 1.  Renal microvascular endothelial cell responses in sepsis-induced acute kidney injury.

Authors:  Grietje Molema; Jan G Zijlstra; Matijs van Meurs; Jan A A M Kamps
Journal:  Nat Rev Nephrol       Date:  2021-10-19       Impact factor: 28.314

2.  Early prolonged neutrophil activation in critically ill patients with sepsis.

Authors:  Sanna Törnblom; Sara Nisula; Suvi T Vaara; Meri Poukkanen; Sture Andersson; Ville Pettilä; Eero Pesonen
Journal:  Innate Immun       Date:  2021-01-18       Impact factor: 2.680

Review 3.  Phosphodiesterase-4 Inhibitor Roflumilast-Mediated Protective Effect in Sepsis-Induced Late-Phase Event of Acute Kidney Injury: A Narrative Review.

Authors:  Imran Kazmi; Fahad A Al-Abbasi; Muhammad Afzal; Muhammad Shahid Nadeem; Hisham N Altayb; Gaurav Gupta
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-20

4.  The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials.

Authors:  Giovanni Landoni; Alberto Zangrillo; Gioia Piersanti; Tommaso Scquizzato; Lorenzo Piemonti
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 5.  Kynurenine Pathway-An Underestimated Factor Modulating Innate Immunity in Sepsis-Induced Acute Kidney Injury?

Authors:  Anna Krupa; Mikolaj M Krupa; Krystyna Pawlak
Journal:  Cells       Date:  2022-08-21       Impact factor: 7.666

6.  Bioinformatics Analysis for Multiple Gene Expression Profiles in Sepsis.

Authors:  Jianhua Zhai; Anlong Qi; Yan Zhang; Lina Jiao; Yancun Liu; Songtao Shou
Journal:  Med Sci Monit       Date:  2020-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.